---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-238959"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2024-10-17T23:59:59+00:00"
generated_at: "2026-05-30T13:17:39.970345+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences: 4 of 5 low-grade NMIBC patients achieve clinical complete response with single-dose bel-sar

## Summary
- Phase 1 trial of bel-sar in NMIBC: 4 of 5 low-grade patients had complete response (no tumor cells on histopathology).
- 2 of 3 high-grade patients showed visual tumor shrinkage on cystoscopy; immune activation observed in all evaluable patients.
- Safety: only Grade 1 drug-related AEs in <10% of patients; no serious adverse events reported as of Sept 9, 2024 cutoff.
- Evidence of bladder urothelial field effect in non-target tumors, suggesting broader immune response.
- Company plans to expand Phase 1 and prepare for Phase 2 trial to evaluate durability of response.

## SEC filing metadata
- accession: 0001193125-24-238959
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2024-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312524238959/0001193125-24-238959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312524238959/d818130d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-238959
- JSON: https://secwatch.observer/filing/0001193125-24-238959.json
- Plain text: https://secwatch.observer/filing/0001193125-24-238959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.